Compound optimal allocations for survival clinical trials

Area of Science:

• Biostatistics
• Clinical Trial Design
• Survival Analysis

Background:

• Comparative clinical trials with survival outcomes require careful patient allocation.
• Balancing inferential demands (e.g., power, estimation efficiency) with ethical concerns (e.g., minimizing patient exposure to suboptimal treatments) is crucial.
• Existing methods may not optimally address both aspects simultaneously.

Purpose of the Study:

• To propose optimal patient allocation strategies for comparative clinical trials focusing on survival outcomes.
• To develop a compound optimization strategy that subjectively weights the importance of statistical inference and ethical considerations.
• To ensure that the proposed methods can be implemented using standard response-adaptive randomization procedures.

Main Methods:

• A compound optimization strategy is employed, integrating inferential demands and ethical concerns.
• Optimal targets are derived as continuous functions of treatment effects.
• Conditions for approximating these targets with response-adaptive randomization are established, ensuring classical asymptotic inference.
• Methodology is validated through theoretical analysis and simulation studies, assessing robustness to model misspecification.

Main Results:

• The proposed strategy consistently allocates more patients to the superior treatment arm.
• This allocation is achieved without compromising statistical inference, including estimation efficiency and statistical power.
• The method demonstrates robustness to potential model misspecifications.
• Simulations confirm the theoretical operating characteristics of the proposed allocation procedure.

Conclusions:

• The developed methodology offers an improved approach to patient allocation in survival outcome clinical trials.
• It effectively balances statistical rigor with ethical imperatives, prioritizing patient well-being.
• The procedure is practical, adaptable to standard randomization techniques, and illustrated with real-world oncological trial examples.